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INTRODUCTION
Synthetic cannabinoids (SCBs) are classified as new psychoactive substances (NPS). There are various types of SCBs available, K2, and Spice being the most popular products. They have gained popularity among peddlers and users because not all are listed as controlled sub stances, they are freely available, they are relatively inexpensive and most importantly they are not dete ctable by routine drug screening methods [1] . SBCs have a wide array of adverse effects and toxicities, ranging from nausea to agitation, seizures, stroke and multiorgan failure. These adverse effects led 28531 patients to the emergency departments in the United States in 2011 [2] . We report a case of bilateral cortical necrosis associated with the use of SCBs.
CASE REPORT
A 47yearold Caucasian female presented to the emergency department with complaints of nausea and vomiting for 5 d along with hallucinations, abdominal pain and severe back pain with hematuria which progressed to anuria over the next 24 h. She admitted to smoking marijuana and stated that she had recently switched to a new dealer and smoked SCB 5 d ago. Past medical history included thyroid cancer status post thyroidectomy followed by radioactive iodine therapy 10 years ago, interosseous lipoma, hyperlipidemia, history of polysubstance abuse, tobacco abuse and history of bipolar disorder.
On physical exam she was ill appearing, hypotensive with a blood pressure of 71/48 mmHg. Pupils were 2 mm in size and sluggish. Lung exam noted diminished breath sounds in the left lower lobe along with bilateral costovertebral angle tenderness.
The patient was admitted to the intensive care unit, intravenous fluid bolus was initiated and nephrology service was consulted. Blood cultures were obtained to rule out sepsis, serum toxicology was positive for benzodiazepines and tetrahydrocannabinol. Laboratory results showed WBC 33. Abdominal cat scan showed a striated appearance of both kidneys. Hemodialysis was initiated on day three.
Computed tomography (CT) guided kidney biopsy was obtained on day ten. The biopsy contained adequate amount of renal cortex with 19 glomeruli. Except for the corticomedullary junction, the entire cortex was necrotic ( Figure 1A and B). At the corticomedullary junction, an arcuate artery had severely obliterating mucoid to fibrous intimal thickening (Figure 1C) . Occasional arterioles at the corticomedullary junctions were obliterated by amorphous material, most likely platelet and fibrin thrombi ( Figure 1D ). Some interstitial inflammation was evident at the corticomedullary junction ( Figure  1A and D). The renal medulla was viable. The tissue for immunofluorescence and electron microscopy represented a completely necrotic renal cortex (pictures not shown). The biopsy findings were consistent with a severe form of thrombotic microangiopathy (TMA) causing renal cortical necrosis.
DISCUSSION
This case illustrates the extent of toxicity of SCBs with recreational use. Use of SCBs has been reported to be associated with devastating renal outcomes and multiorgan failure in patients. Most of these reports suggested prerenal azotemia and rhabdomyolysis as the cause of acute tubular necrosis [1] . In 2013 the center for disease control reported a case series of 16 patients who developed acute kidney injury while using SCBs [3] . Majority (93.8%) of the patients presented with nausea and vomiting, 12 (75%) patients had either abdominal pain or flank pain and only 1 patient had anuria.
Physiological effects of SCB's are similar but more intense than cannabinoids. This is related to the greater binding affinity to cannabinoid receptors centrally and peripherally as well as their active metabolites that contribute to the intensity of their effects [4] . Similar to cannabinoids and following a brief pressor phase, SCB's can cause longstanding hypotension and bradycardia as a result of a decrease in the sympathetic tone [5] . Nonneural sites of the cannabinoids action on the vascular smooth muscle and endothelial cells can also add to the degree of systemic hypotension [6] . Animal studies in canines and rodents using different vascular beds suggested a direct effect of cannabinoids on smooth muscle cells mediated through the modulation of calcium and potassium cellular transport resulting in hyperpolarization and relaxation [7, 8] . Cannabinoids also have endothelialdependent effects on the vascular beds. This can be initiated by binding to CB1 receptors on the surface of the endothelial cell and to a different type of receptor that might not be specific to the class of cannabinoids [6] . Taken all together, it is reasonable to state that SCB is a more potent drug than the natural cannabinoids can potentially result in major vascular compromise followed by stasis secondary to vascular paralysis. This state can result in anoxic endothelial cell damage that leads to thrombotic microangipathy. In our patient, this is suggested by laboratory markers of compromised organ perfusion along with thrombocytopenia. Figure 2 illustrates the mechanism of TMA in this patient.
Alternative etiologies of TMA were either ruled out or were unlikely in this patient with a temporal relationship between the exposure and the onset of clinical manifestations. An underlying tendency or inherited alternative complement pathway abnormalities as in hemolytic uremic syndrome is also unlikely, as the systemic presentation was suggestive of multi organ intense hypoperfusion rather than primary renal involvement. Moreover, the normal complement levels, although a nonspecific finding, add to this argument. To our knowledge, this is the first case that shows biopsy proven cortical necrosis due to SCB use. Three years later, our patient is still dialysis dependent. 
